Every one of those 1 sits in a single category, ipo. Of the tracked stories, 1 of 1 also mention Gaudium IVF and Women Health, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Hem Securities
Every one of those 1 sits in a single category, ipo. Of the tracked stories, 1 of 1 also mention Gaudium IVF and Women Health, the most common co-covered peer. They are better corroborated than the beat average, carrying 3 original sources each against 2.4 for the same window. The 5 average consequence score is below the beat benchmark of 6.5 in the same window. Hem Securities appears in 1 tracked Startup story from February 24, 2026.
Stories tracked
1
Sources per story
3
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 32 Startup stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Hem Securities. Shared-story counts are live from our verified record — not editorial picks.
Gaudium IVF and Women Health's ₹125.22 crore IPO entered its final bidding day with a 3x overall subscription and a steady grey market premium. The offering, consisting entirely of a fresh issue, has seen particularly robust interest from retail investors as the company seeks to expand its fertility clinic network.